Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rogaratinib - Bayer

Next Previous
Drug Profile

Rogaratinib - Bayer

Alternative Names: BAY-1163877

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Bayer; Fundacion CRIS de Investigacion para Vencer el Cancer; Swiss Group for Clinical Cancer Research
  • Class Amines; Antineoplastics; Piperazines; Pyrroles; Small molecules; Thiophenes; Triazines
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Urogenital cancer
  • Phase II Gastrointestinal stromal tumours; Sarcoma
  • No development reported Breast cancer; Solid tumours
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 25 Apr 2025 Efficacy, pharmacodynamics and adverse events data from a phase II trial in Gastrointestinal stromal tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 10 Dec 2024 Efficacy and safety data from the phase I ROGABREAST trial in Breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 03 Oct 2024 Bayer completes phase-I/II clinical trials in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in Austria, Spain, Italy, France, Japan, Germany, South Korea and USA (PO) (NCT03473756)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top